PHPeter Hellstern

Peter Hellstern

*This is an algorithmically generated author record based on publicly available information.

Peter Hellstern has a total of 88 co-authors. Here are the top co-authors by number of shared publications:

  • H. Haubelt

    Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital, Ludwigshafen

    7 shared publications
  • Hannelore Haubelt

    Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital, Ludwigshafen, Germany

    6 shared publications
  • A. Vogt

    Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital, Ludwigshafen

    4 shared publications
  • C. Anders

    Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital, Ludwigshafen, Germany

    4 shared publications
  • J. Bach

    Institute of Hemostaseology and Transfusion Medicine, Academic City Hospital, Ludwigshafen, Germany

    3 shared publications
  • Michael Köhler

    3 shared publications

Latest Publications

  • Open Access

    The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma

    by Peter Hellstern, Bjarte G. Solheim

    The solvent/detergent (SD) process used for plasma can safely inactivate all lipid-enveloped viruses. The introduction of a specific prion-binding ligand gel in combination with SD treatment, time-reduced from 4 to 1–1.5 h, still ensures efficient virus kill, reduces abnormal prion protein by >5 log steps, and preserves levels of plasmin inhibitor at close to the reference range. Infections with known non-enveloped viruses such as HAV or parvovirus B19 are prevented by ensuring low virus loads in the starting plasma units, dilution through pooling of single plasma units, and neutralization of immune antibodies already present in the initial plasma pools. The major advantages of SD plasma over fresh frozen plasma and the other pathogen-inactivated plasmas are its extreme safety with respect to transfusion-related acute lung injury and the significantly lower likelihood of provoking allergic reactions. Both advantages are best interpreted as results of the dilution effect of pooling. No fewer than 18 clinical studies covering all indications for plasma, and extensive clinical experience have shown that reduced levels of coagulation factors and inhibitors as a result of SD treatment do not impair significantly the clinical efficacy or tolerance of plasma. Properly standardized clotting factor and inhibitor potencies and low batch-to-batch variations when compared with single-donor plasma units makes SD plasma more suitable for standardized treatment.


  • Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk

    by J. Bach, G. Endler, B. R. Winkelmann, B. O. Boehm, W. Maerz, C. Mannhalter, P. Hellstern


  • Efficacy and Adverse Events of Platelet Transfusion – Product-Specific Differences

    by Peter Hellstern

    Two preparations are available for platelet transfusion: single-donor apheresis platelet concentrates (APC) and pooled platelet concentrates (PPC) prepared from 4–6 whole blood units. Clear advantages of APC over PPC are a markedly reduced donor exposure of recipients, and easier logistics when attempting a complete supply with ABO-identical and Rh-compatible platelet concentrates. Regulations should aim at complete ABO-identical platelet transfusions because major and minor ABO-incompatible platelet transfusions are probably associated with significantly increased morbidity and mortality. The main advantage of PPC is lower costs. Preparation of PPC is however inevitably accompanied by substantial wastage of plasma and red cells. Only major supraregional blood transfusion centers can guarantee full-coverage supply with ABO-identical and Rh-compatible PPC. Whether APC are more effective than PPC and associated with fewer septic platelet transfusion reactions as shown in some but not all studies, has to be examined in future prospective controlled trials.


  • Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin

    by P. Hellstern, U. Stürzebecher, B. Wuchold, H. Haubelt, U. T. Seyfert, M. Bauer, A. Vogt, J. Stürzebecher


  • Retracted

    THIS ARTICLE HAS BEEN RETRACTED The impact of a medium molecular weight, low molar substitution hydroxyethyl starch dissolved in a physiologically balanced electrolyte solution on blood coagulation and platelet function in vitro

    by J. Boldt, A. Mengistu, U. T. Seyfert, A. Vogt, P. Hellstern

    Hydroxyethyl starches (HES) may have the potential to impact negatively on haemostasis. Recent findings suggest that side-effects on haemostasis stem not only from the physicochemical differences between HES, but also from the composition of the solvent. We compared the effects of a newly developed medium molecular weight (MW) and low molar substitution (MS) HES dissolved in a physiologically balanced electrolyte solution (MW 130, MS 0.42; B-HES) with a commercially available non-balanced HES (MW 130, MS 0.4; NB-HES), and with Ringer's lactate (RL) solution in vitro. Activated partial thromboplastin time (APTT), factor VIII clotting activity (F VIII:C) and von Willebrand factor (vWF) activity were investigated in 48 healthy individuals. Platelet function as measured by turbidimetric platelet aggregometry and whole blood impedance aggregometry induced by adenosine diphosphate (ADP), collagen and thrombin receptor activating peptide (TRAP), and by ADP and TRAP-induced expression of activated platelet fibrinogen receptor glycoprotein (GP) IIb/IIIa was determined in 24 participants. Haemodilution (25% and 50%, v/v for blood coagulation analyses and 20% and 40%, v/v for platelet function studies) was performed using the two HES preparations and RL. APTT was significantly longer and F VIII and vWF significantly lower at 25% and 50% dilutions with NB-HES compared to B-HES and RL. At 20% and 40% dilutions, ADP and TRAP-induced expression of activated platelet surface GP IIb/IIIa was significantly increased by B-HES compared to NB-HES and RL. Percentages of platelet GP IIb/IIIa expression were also significantly greater in samples diluted with B-HES than in undiluted blood. Neither the diluent (B-HES, NB-HES and RL) nor the degree of dilution (undiluted, 20% and 40% dilution) had any significant influence on ADP, collagen or TRAP-induced turbidimetric platelet aggregation or impedance platelet aggregation. In contrast to a non-balanced 130 kDa, MS 0.4 HES (NB-HES), a 130 kDa, MS 0.42 HES preparation dissolved in a physiologically balanced electrolyte solution (B-HES) does not affect APTT, F VIII:C and vWF in vitro. Both types of HES do not affect platelet aggregation induced by ADP, collagen or TRAP. B-HES but not NB-HES increases the expression of activated platelet GP IIb/IIIa induced by ADP or TRAP.


  • Open Access

    Heparin Monitoring During Cardiopulmonary Bypass Surgery Using the One-Step Point-of-Care Whole Blood Anti-Factor-Xa Clotting Assay Heptest-POC-Hi

    by Peter Hellstern, Juergen Bach, Melanie Simon, Werner Saggau

    The activated clotting time (ACT) generally used for monitoring heparinization during cardiopulmonary bypass (CPB) surgery does not specifically measure heparin anticoagulant activities. This may result in heparin over- or under-dose and subsequent severe adverse events. A new point-of-care whole blood clotting assay (Heptest POC-Hi [HPOCH]) for quantifying heparin anticoagulant activity specifically was compared with ACT and anti-factor Xa (anti-Xa) heparin plasma levels (Coatest heparin) in 125 patients undergoing CPB surgery. The analytical reliability of the HPOCH and the influence of preanalytical variables on assay results were also examined. The ACT and HPOCH clotting times determined throughout the entire observation period correlated closely (n= 683;r= 0.80;p< .0001). Similarly, there was a significant linear correlation between HPOCH and Coatest anti-Xa levels (n= 352;r= 0.87;p< .0001). Pre- and post-CBP values of HPOCH, ACT, and anti-Xa plasma levels correlated closely with each other (correlation coefficients betweenr= 0.90 andr= 0.99;p< .0001). During CPB, there was no significant relationship between ACT and whole blood or plasma heparin levels determined by HPOCH (n= 157;r= 0.19) and the chromogenic anti-Xa assay (n= 157;r= 0.04), respectively. In contrast, HPOCH and anti-Xa plasma levels correlated strongly during CPB (n= 157;r= 0.57;p< .0001). However, bias analysis showed that the HPOCH and Coatest heparin could not be used interchangeably. The HPOCH was well reproducible and not influenced by aprotinin, hemodilution, or other factors affecting ACT. The HPOCH seems to be a promising new tool for specific on-site measurement of heparin activities in whole blood during CPB.


  • A prospective multicentre study on the safety of long‐term intensive plasmapheresis in donors (SIPLA)

    by T. Schulzki, K. Seidel, H. Storch, H. Karges, S. Kiessig, S. Schneider, U. Taborski, K. Wolter, D. Steppat, E. Behm, et al.

    Background and Objectives  The safety of chronic intensive donor plasmapheresis has not been determined in large prospective studies examining dropout rates, dropout reasons and predictors of withdrawals.Materials and Methods  Twenty‐one plasma centres recruited 3783 donors who were switched from a moderate to an intensive plasmapheresis programme and observed over a 3‐year period. Individuals weighing < 70 kg and ≥ 70 kg donated 750 ml and 850 ml of plasma per session, respectively. The maximum of annual donations was limited to 60. Total serum protein (TSP) and haemoglobin (Hb) or haematocrit (Hct) were determined at each donation, and immunoglobulin G (IgG) at every fifth donation. Dropout rates, dropout reasons and potential predictors of withdrawal were analysed.Results  Dropouts were predominantly due to socioeconomic (49·2% of all donors) or medical reasons not related to plasma donations (10·4% of all donors). Sixteen per cent of donors dropped out when IgG, TSP or Hb levels fell below threshold values. Severe clinical adverse events related to plasmapheresis were observed in five subjects. The incidence in severe cardiovascular diseases was lower in donors than in the general population. The risk factors that led to dropping out as a result of low IgG, TSP or Hb levels included younger age, female gender, low initial IgG levels and a high donation frequency. Neither body weight nor the amounts of plasma donated per kilogram of body weight per session were associated with ceasing due to medical reasons, whether related or unrelated to plasma donations. Females and males within the respective lowest body weight category were not at higher risk of dropping out.Conclusion  Long‐term intensive donor plasmapheresis under conditions investigated in this study is safe. All donors weighing ≥ 70 kg are safely able to donate 850 ml of plasma in each session up to 60 times per year, provided that they are carefully monitored.